Christopher James Frankenfield - 03 Aug 2023 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Chief Operating Officer
Signature
/s/ Julia Walcott, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
03 Aug 2023
Transactions value $
$0
Form type
4
Filing time
07 Aug 2023, 16:12:19 UTC
Next filing
18 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (Right to Buy) Award $0 +150K $0.00 150K 03 Aug 2023 Common Stock 150K $2.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on August 3, 2023 and will vest in equal monthly installments beginning on September 1, 2023 through August 1, 2027.